



**OUTLINE OF ACTIVE TRIALS WITH NIVOLUMAB  
JULY 2021**

---

**Study Title:** A Phase 2a, Open-Label Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB)

**Sponsor:** Gilead Sciences, Inc.  
333 Lakeside Drive  
Foster City  
CA 94404  
USA

**EudraCT Number:** 2021-000672-11

**Indication:** Chronic hepatitis B virus (HBV) infection

**Protocol ID:** GS-US-465-4439

There are currently no Gilead sponsored Nivolumab clinical trials ongoing, approved or under assessment in the European Union.